Right. But there would need to be a reason to believe such a $3 billion market cap would be justified.
Assume the market suddenly decides this year that B-UP will succeed and sell $300M/year (very very bullish sales case).
$300M/year * 6% = $18M/year in royalties.
Add a 5 year multiple to these and our royalties on B-UP are worth $90M. Add the $24M in milestones and that brings you to $114M B-UP total projected revenue. We won't see more than $6M of that for at least 3 years though.
Let's call the upfront payment $30M.
Cash: $30M
B-ABSSSI: ? How much is this worth? The phase 3 is pretty much a guaranteed success based on the phase 2b results. $30M to run it or so. We have completely derisked this one.
B-OM: ? Hard to value. The drug is effective and safe. It has the superior delivery method among all potential competitors.
Kevetrin: ? B-UC: ? B-IBD: ? B-UP: $114M
Just curious how you get the values to add up to $3B in the next two months. Speculation could bring us to $300M if there is evidence that the upfront payment was $30M. $3B though?